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Abstract
Data on the prevalence of benign and malignant nodular thyroid disease in patients with acromegaly is a matter of debate.
In the last decade an increasing incidence of thyroid cancer has been reported. The aim of this study was to evaluate the
prevalence of goiter, thyroid nodules and thyroid cancer in a large series of patients with acromegaly with a cross-sectional
study with a control group. Six Spanish university hospitals participated. One hundred and twenty three patients (50% men;
mean age 59613 years; disease duration 6.767.2 years) and 50 controls (51% males, mean age 58615 years) were studied.
All participants underwent thyroid ultrasound and fine needle aspiration. Cytological analysis was performed in suspicious
nodules between 0.5 and 1.0 cm and in all nodules greater than 1.0 cm. Goiter was more frequently found in patients than
in controls (24.9 vs. 8.3%, respectively; p,0.001). Nodular thyroid disease as well as nodules greater than 1 cm were also
more prevalent in acromegalic patients (64.6%, vs. 28.6%, p,0.05 and 53.3 vs. 28.6%, respectively; p,0.05), and all
underwent fine needle aspiration. Suspicious cytology was detected in 4 patients and in none of the controls. After
thyroidectomy, papillary thyroid carcinoma was confirmed in two cases (3.3% of patients with thyroid nodules),
representing 1.6% of the entire group of patients with acromegaly (2.4% including a case with previously diagnosed
papillary thyroid carcinoma). These data indicated that thyroid nodular disease and cancer are increased in acromegaly, thus
justifying its routine ultrasound screening.
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Introduction
Acromegaly is an endocrine disorder characterized by growth
hormone (GH) hypersecretion mainly due to a pituitary micro or
macroadenoma [1]. In the majority of patients GH excess
produces an overgrowth of acral parts of the body. Organs such
as the liver or the heart may also increase in size and joint articular
cartilage thickness, vertebral fractures, left ventricular dysfunction,
abnormal lipid profile, and obstructive apnea events may appear
with different reported prevalence [2]. Moreover, long term
exposure to GH and insulin-like growth factor (IGF)-1 could
induce proliferative capacity and increases the likelihood of
developing malignancies [3], colorectal cancer being the most
frequently observed neoplasm in acromegalic patients. Therefore,
colonoscopy is recommended for early detection and removal of
pre-malignant intestinal polyps and colorectal cancer [4].
Nodular thyroid disease and goiter are frequent conditions in
the general population, with an age-related increasing incidence
reaching 30–50% in people over 50 years in ultrasound studies [5].
Most of these nodules are benign, but the overall reported
malignancies rate is about 5–10% [6]. The age-standardized
incidence of thyroid cancer is estimated to be 0.9% (females) and
0.2% (males) in developed countries and related to iodine
deficiency status [7].
The prevalence of benign nodular thyroid disease and
malignancy in patients with acromegaly has been a matter of
debate. In previous studies performed many years ago [8–11],
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goiter and thyroid nodules appeared to be more frequent among
patients with acromegaly, but the prevalence of thyroid carcinoma
was thought to be low, and its true incidence was unknown. More
recent studies [12–15] have reported an overwhelming increase in
thyroid cancer prevalence (11.0, 7.2, 7.8 and 10.6%, respectively).
However, only the one by dos Santos et al. [13] evaluated a
significantly large number of patients in a cross-sectional protocol,
to be considered consistent enough. The other studies from the
same institution [14,15], are retrospective [14,15] and included a
limited number of patients [12,14,15].
Thus, the true prevalence of thyroid nodules and thyroid cancer
in acromegaly warrants further assessment, with more studies in
different geographical areas and including a contemporary control
group.
Therefore, our objective was to evaluate the prevalence of
goiter, thyroid nodules and thyroid cancer in a large series of
acromegaly patients in Spain, compared to an age- and sex-
matched control group.
Materials and Methods
Patients
We conducted a multicenter cross-sectional study including a
control group. Patients followed for acromegaly were recruited
from the outpatient clinics of six university hospitals in Spain:
Santa Creu i Sant Pau University Hospital, Clinic University
Hospital and Hospital Universitari Quiron-Dexeus, all in
Barcelona, Germans Trias i Pujol University Hospital in
Badalona, Arnau de Vilanova University Hospital in Lleida, and
Hospital de la Ribera in Alzira, Valencia. All these hospitals are
located in non-iodine deficient areas [16]. The control group was
composed by otherwise healthy subjects over 18 years-old. The
study was conducted in accordance with the Declaration of
Helsinki and was approved by the relevant local Human Research
Ethics Committee (Comite´ d’E`tica de la Investigacio´ Clı´nica,
CEIC, Hospital Germans Trias i Pujol de Badalona). All
participants gave written informed consent.
Methods
All patients actively followed-up in the different institutions were
invited to participate. From an original cohort of 140 patients, 123
accepted the invitation. Seventeen were not included due to non-
medical reasons. Diagnosis of acromegaly was confirmed when
elevated IGF-1 levels (adjusted for sex and age) and GH levels
greater than 1 ng/mL after an oral glucose tolerance test with
75 g of dextrose and a pituitary adenoma identified by conven-
tional imaging techniques. All patients were treated following
institutional protocols and international guidelines for acromegaly
management, with surgery, medical therapy (somatostatin ana-
logues, cabergoline or pegvisomant) and external radiation when
needed [4,17,18]. Disease duration, time from first symptoms, age
at diagnosis, treatment modalities and history of thyroid disorders
were recorded for each patient. Duration of disease was
considered from the date of diagnosis to evaluation.
Serum GH levels were locally measured in each participating
center by chemiluminescent assay and serum IGF-1 levels were
measured at each site by immunometric chemiluminescent
immunoassay; serum free thyroxine (fT4) and TSH were
measured by electrochemiluminescence immunoassay (Siemens,
Los Angeles, CA, USA).
In each patient an ultrasound examination was performed using
a 7.5–12 MHz linear transducer device by experienced operators
(JLR, VR) in two centres using a common protocol. Morpholog-
ical evaluation included the description of thyroid echostructure
and the measurement of the diameters of each thyroid lobe and
isthmus. Volumetric assessment of the thyroid gland was based on
the use of an ellipsoid model [19]. With this rotating ellipsoid
model, the height, width, and depth of each lobe were measured
and multiplied. The obtained result was then multiplied by the
mathematical constant or correction factor 0.524 [20]. The result
is the estimated value of the volume of each lobe and the isthmus;
this procedure is also performed for determining the volume of the
isthmus. Thus, calculation of the total volume of the gland results
from the sum of the volume of each lobe and the volume of the
isthmus. According to the reference values obtained in the
population in our area, the mean normal gland volume of an
adult individual has been estimated to be 9.19 mL (CI: 9.87–
10.65 mL) in men and 6.19 mL (CI: 6.22–6.92 mL) in women
[21].
All the nodules detected were measured and their ultrasound
characteristics were registered; cervical lymph nodes were also
evaluated. Fine-needle aspiration (FNA) cytology was performed
in all nodules larger than 1.0 cm of diameter and in those between
0.5 and 1.0 cm if they presented suspicious ultrasound character-
istics according to the American Society of Ultrasonography [22],
such as the presence of microcalcifications, irregular borders,
increased central flow on Doppler examination, taller than wide
diameter, hypoechogenicity and absence of halo. FNA was
performed using a 25 GA needle (Becton, Dickinson and
Company, Sparks, MD, USA), and guided by ultrasound in two
centres (JLR,VR) using the same protocol. The slides were air-
dried, and then stained with Giemsa. Two pathologists evaluated
the samples. The nodules with a suspicious or firm diagnosis of
thyroid carcinoma in FNA cytology were referred for thyroidec-
tomy.
Statistical analysis
Continuous variables were expressed as mean 6 SD and
categorical variables as percentages. Student’s t test was used for
comparisons between continuous variables and Pearson’s correla-
tion test for correlation analyses. A p value ,0.05 was considered
statistically significant and correlations were considered significant
for Pearson’s correlation coefficient if $0.25. For comparison of
categorical variables, the Chi-squared test or the Fisher exact test
were used where appropriate. Data analyses were performed using
Statistical Package for Social Sciences (SPSS, Chicago, IL, USA)
for Windows, Version 15.0.
Results
Subjects characteristics
The subjects of this study were 123 acromegalic patients (50%
males), with a mean age of 59613 years. Time between initial
symptoms and diagnosis was 5.465.2 years. Disease duration from
diagnosis was 6.767.2 years. Family history revealed goiter or
thyroid disease in 2.9% of the patients. Nine cases had undergone
previous thyroid surgery for well documented benign nodular
goiter and one case for papillary thyroid carcinoma. A GH
producing macroadenoma was the cause of acromegaly in 73.4%
of the cases and in the remaining 16.6% a microadenoma. Ninety
seven percent underwent neurosurgical treatment, and external
radiotherapy was performed in 36.6%.
With regards to disease status at the time of the present study,
51.4% of patients still had active disease and were under medical
therapy. Of those: 63.4% were treated with long-acting somato-
statin analogues, 29.6% with cabergoline and 27.8% with
pegvisomant. Table 1 shows clinical and analytical characteristics
of patients with active and cured disease. Last serum IGF-1 was
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significantly lower in cured patients compared to non-cured
(197.2672.0 ng/mL vs. 258.16147.5 ng/mL, respectively,
p = 0.02). The 52.5% of patients had no associated pituitary
hormone deficiencies, whereas the rest required one (37.5%) or
multiple (10%) substitution therapies.
The control group was composed of 50 volunteers (51% males)
with a mean age of 58615 years.
Ultrasound characteristics
The results of ultrasound examination and FNA are depicted in
Table 2. Thyroid volumes obtained in the control group were
similar to those previously observed in a population of the same
geographical area with a similar iodine intake [21]. The overall
group of acromegalic patients showed an increased thyroid volume
compared to the control group (12.667.5 vs. 8.064.5 mL, p,
0.001). This difference was also observed when comparing male
and female patients with their respective controls. Acromegalic
male patients presented non-significant greater thyroid volume
compared with females (13.066.3 ml vs. 12.268.9 ml, respec-
tively, p = 0.6). Goiter was more frequently observed in patients
compared to controls (24.9 vs. 8.3%, respectively; p,0.001). As
shown in Figure 1, thyroid volume values presented a normal
distribution in both groups. On the other hand, patients with
active acromegaly showed larger thyroid volumes than those with
cured disease (14.668.7 vs. 10.965.3 mL, respectively; p = 0.03).
Newly discovered nodular thyroid disease was more prevalent in
acromegaly (55.7%), while nodules were detected in one third of
the controls (30.0%, p,0.05). The relative distribution of single
and multiple nodular thyroid disease was different as well, with
more multinodular goiter in acromegalic patients. The overall
prevalence of thyroid nodules in our acromegalic patients reached
64.6% including patients with previously known nodular thyroid
disease.
The size of the nodules was significantly different between
patients and controls. Micronodules ,1 cm were detected more
frequently in controls (71.4%) than in acromegalic patients
(44.7%, p,0.05) who therefore presented a higher prevalence of
clinically significant thyroid nodules. In acromegalic patients, 5%
of the micronodules smaller than 1 cm diameter had suspicious
sonographic features that led to FNA and in all of them the
cytological exam was benign (colloid goiter and thyroid cyst). On
the other hand, none of the micronodules in controls required
cytological evaluation.
Cytological and histopathological diagnosis
FNA was performed in 55.2% of patients with thyroid nodules
and in 28.6% of the controls (p,0.001). As shown in Table 2, the
Table 1. Characteristics of patients with cured acromegaly and active disease.
Cured (n = 63) Active (n = 60) p value
Age (years) 60611 58614 0.4
Initial GH (mg/L) 22.4644 20.7621.6 0.8
Initial IGF-1 (ng/mL) 769.16413.5 939.06460.6 0.1
Last IGF-1 (ng/mL) 197.2672.0 258.16147.5 0.02
TSH* (mU/L) 2.061.7 1.461.2 0.1
Free T4 (ng/dL) 1.160.3 1.260.2 0.6
* Patients without TSH deficiency.
GH: Growth hormone, IGF: Insulin-like growth factor. TSH: Thyrotropin.
doi:10.1371/journal.pone.0104174.t001
Table 2. Sonographic features and cytological diagnosis of patients with acromegaly and controls group.
Acromegaly (n = 123) Controls (n = 50) p value
Thyroid volume (mL) (mean±SD)
- Overall group 12.667.5 8.064.5 ,0.001
- Male 13.066.3 8.865.7 ,0.05
- Female 12.268.9 7.062.5 ,0.05
Thyroid nodules (%) 55.7 30.0 ,0.05
- Solitary 25.5 16.7 ,0.05
- Multiple 30.2 12.5 ,0.05
Nodule diameter ,1 cm (%) 44.7 71.4 ,0.05
FNA* cytology (% of patients with nodules) 55.2 28.6 ,0.001
Diagnosis (% of smears
- Benign 87.0 100.0 ,0.05
- Suspicious for a follicular neoplasm 6.5 0.0 ,0.05
- Malignant (papillary carcinoma 6.5 0.0 ,0.05
* FNA: Fine needle aspiration.
doi:10.1371/journal.pone.0104174.t002
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majority of smears of acromegalic patients were diagnosed as
benign lesions, especially colloid goiter, and to lesser extent thyroid
cysts. Suspicious or malignant cytology was detected in 13.0% of
the FNAs specimens from acromegalic patients. All these patients
with suspicious or positive malignant cytology underwent thyroid-
ectomy. Papillary thyroid carcinoma was confirmed in two cases,
representing 3.2% of patients harbouring thyroid nodules (1.6% of
the overall acromegaly group). The overall prevalence of thyroid
carcinoma, including the patient with previously diagnosis of
papillary thyroid cancer was 2.4%.
None of the nodules cytologically analyzed in the control group
was suspicious or malignant.
Correlation studies
In acromegaly, no correlation was found between thyroid
volume and the duration of the disease, time between the first
symptoms to diagnosis, GH and IGF-1 at diagnosis, and IGF-1 at
last follow-up. Patients with thyroid nodular disease and those with
normal ultrasound presented similar concentrations of GH
(24.643.0 vs. 27.1629.4 mg/L, respectively; p = 0.4) and IGF-1
(867.56438 vs. 825.86525.8 ng/mL, respectively; p = 0.7) at
diagnosis. IGF-1 concentrations at last follow-up were not different
in patients with thyroid nodules (226.36144.8 ng/mL) compared
to patients without thyroid abnormalities (239.76139.6 ng/mL)
(p = 0.7).
Bivariate correlation studies showed that age was positively
correlated with TSH (Rs = 0.2; p = 0.02) whereas thyroid volume
and nodule size were not correlated with TSH, GH or IGF-1
concentrations.
The two cases of newly diagnosed papillary thyroid carcinoma
were observed in active acromegalic patients (one male, one
female), one with a macroadenoma and the other with a
microadenoma diagnosed in 2011 and 2012, respectively. In these
two patients, initial IGF-1 levels were 1453.1 and 533.3 ng/mL,
Figure 1. Thyroid volume (mL) in acromegalic patients (upper panel) and controls (lower panel) following a normal distribution.
doi:10.1371/journal.pone.0104174.g001
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respectively and the size of their nodules was greater than 2 cm.
The case with a previous diagnosis of papillary thyroid cancer
(2 cm diameter) was a male with a pituitary macroadenoma,
diagnosed in 2013 with initial levels of IGF-1 of 894.2 ng/mL.
Discussion
In our series of 123 acromegalic patients accurately explored for
thyroid abnormalities, we found an increased prevalence of goiter
and thyroid nodules and three cases of thyroid cancer. This rate of
thyroid malignancy (2.4%) is lower than previously reported [12–
15], but represents a significant increase with respect to the general
population [23,24]. However, these figures should be interpreted
in parallel to epidemiological data from specific geographical
regions. In this sense, reported thyroid cancer incidence and
prevalence varies considerably in different registries [25–27].
Earlier studies with smaller number of cases and recent data
from a large series of patients reported an overall detection of
goiter of about 20% in patients with acromegaly [13,28]. The
present study, confirms a rate of goiter in acromegalic patients of
24.9%, higher than in the control group (8.3%). Interestingly, as a
group, thyroid volume of the patients followed a normal
distribution, suggesting a generalized effect. Thyroid size was not
related to age or to other clinical and laboratory parameters.
However, as expected, TSH levels in patients not treated with
thyroxine correlated positively with age, but were within the
normal range (data not shown) [29]. The increased thyroid volume
in acromegaly is likely to be a consequence of continuous
stimulation by excessive secretion of GH from the pituitary
adenoma. However, unlike previous studies [14], no correlation
was found between GH or IGF-1 levels at baseline or last follow-
up and thyroid volume. We have not a clear explanation for this
negative finding, but probably individual factors play a role in the
response to GH stimuli. As normal thyroid volume varies
depending on the presence of iodine deficiency, differences in
iodine supplies could also have influenced thyroid growth [30].
The prevalence of thyroid nodules of 55.7% in our study is
similar to that reported by others with a similar number of studied
cases (54%) [13] and is even more pronounced (64.6%) when
considering patients with a previous diagnosis of nodular thyroid
disease. However, in comparison to previous reports [13,14], we
found more nodules of a diameter greater than 1 cm and for this
reason more FNA cytological evaluations have been performed,
the majority being benign. As expected in the general population,
nodular thyroid disease was detected in about one third of
controls, similar to data from other European epidemiological
studies [31], with no thyroid cancer found. Iodine intake in our
population [30] could influence this proportion of thyroid nodules.
On the other hand, a higher number of micronodules (,1 cm)
were observed in controls than in patients with acromegaly.
Prolonged exposure to high levels of GH and/or IGF-1 may be
the basis of this increase in the frequency and size of the nodules.
Growth hormone and IGF-1 have both well known proliferative
and anti-apoptotic effects and their hypersecretion may theoret-
ically induce tumor development and stimulate its growth.
Although the influence of acromegaly on carcinogenesis remains
controversial, several studies indicate that the rate of tumors in
these patients is higher. In this regard, acromegaly has been
associated with both benign and malignant tumors, and carcinoma
is the third cause of death in acromegalic patients [18]. Therefore,
active detection of colon cancer is recommended in international
guidelines [4]. Regarding thyroid cancer, this issue continues to be
controversial so far [32] and, specific recommendations for
ultrasound screening have not been included in recent guidelines
[4]. As thyroid follicular cells express IGF-1 receptors and IGF-1 is
a well recognized growth factor for thyrocites, it may be speculated
that IGF-1 has a potential role in the development of thyroid
cancer in acromegalic patients. However, no difference was found
in GH/IGF-1 concentrations in patients with and without thyroid
cancer. On the other hand, IGF-1 receptor expression in thyroid
cancer samples was not evaluated. Individual sensitivity, epigenetic
modifications, different patterns of GH/IGF-1 secretion over time
and other factors yet unknown could explain this lack of
differences.
At present, due to the improvement in surgical and radiother-
apeutic procedures [33,34] as well as the advances in medical
treatment [35], survival of patients with acromegaly has substan-
tially improved. Therefore, the appearance of slow-growing
tumors that could compromise quality of life or survival is a
reasonable possibility dueto the frequently long delay in the
diagnosis of acromegaly, causing long exposure to high GH levels.
Thyroid carcinoma is generally characterized by its low
aggressiveness [23,24]. However, between 15 and 25% of cases
may undergo a dedifferentiation process with loss of the ability to
trap radioiodine, making this treatment ineffective, and worsening
the prognosis [36,37].
Few studies have focused on the incidence of thyroid cancer in
acromegaly using ultrasound examination and FNA biopsy [13–
15]. Among these, only one has been able to include more than
one hundred patients with a multicenter design [13]. A feature of
more recent reports, two retrospective studies from the same
Turkish group [14,15] and one cross-sectional from Brazil, is the
remarkable high prevalence of thyroid cancer found, which
reached 7.8% [14], 10.6% [15] and 7.2% [13]. In our cases we
would have expected at least 7 to 12 thyroid carcinomas.
However, the diagnosis of two new cases of papillary thyroid
cancer in our series is far from these previous observations. This
discrepancy may be due to geographical, ethnic or environmental
reasons such as iodine intake or the prevalence of thyroid
autoimmunity. Even so, the prevalence found in the present study
represents a significant increase with respect to the general
population. Moreover newly discovered nodular thyroid disease
was more prevalent in acromegalic patients, with a higher
prevalence of goiter. These data support, in our opinion, the
recommendation for routine thyroid ultrasound for systematic
detection of thyroid cancer in acromegaly and FNA cytology when
indicated.
In a recent meta-analysis and systematic review in this topic
[38], the authors state that the amount of reliable papers including
controls groups and data of both on the prevalence of thyroid
nodular disease and thyroid cancer is unsatisfactory. The main
strengths of our study are the non-retrospective design, the sample
size achieved by the multicenter approach, the systematic
exploration of thyroid gland by using high sensitive ultrasound
devices and the standardized defined nodule characteristics for
FNA cytology. Furthermore, to our knowledge, this is the largest
study in this issue performed in Western European countries in the
last decade after the Italian multicenter study [8]. Locally
determined GH and IGF-1 in each participating center may
influence the correlation studies, but not the results referring to
thyroid nodules and cancer prevalence. The number of the control
subjects is adequate to make a conclusion about thyroid volume
and goiter prevalence but could be insufficient for detection of
thyroid cancer. However, this fact does not influence the objective
assessment of the number of malignant tumors found in the
patients.
Benign and Malignant Thyroid Disease in Acromegaly
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In conclusion, thyroid nodular disease and thyroid malignancy
are increased in acromegaly compared to the general population,
thus justifying its systematic ultrasound screening.
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